5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
Infusion O
reactions O
may O
occur O
. O

Premedicate O
with O
diphenhydramine O
. O

Slow O
or O
interrupt O
infusion O
and O
administer O
treatment O
based O
on O
severity O
of O
the O
reaction O
. O

( O
5.1 O
) O
5.1 O
Infusion O
Reactions O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
reported O
during O
administration O
of O
raxibacumab O
in O
clinical O
trials O
including O
reports O
of O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
pruritus B-OSE_Labeled_AE
. O

If O
these O
reactions O
occur O
, O
slow O
or O
interrupt O
raxibacumab O
infusion O
and O
administer O
appropriate O
treatment O
based O
on O
severity O
of O
the O
reaction O
. O

Premedicate O
with O
diphenhydramine O
within O
1 O
hour O
prior O
to O
administering O
raxibacumab O
to O
reduce O
the O
risk O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

